IDO1 and neoplasm: Although CD4+CD25hiFoxP3+ T cell depletion strategies turned out not to be robust enough to allow implementation into a clinical protocol aiming at improved generation of tumor-reactive T cells, inhibition of IDO and galectin-3 proved to be successful.